JP2019524100A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524100A5 JP2019524100A5 JP2019502217A JP2019502217A JP2019524100A5 JP 2019524100 A5 JP2019524100 A5 JP 2019524100A5 JP 2019502217 A JP2019502217 A JP 2019502217A JP 2019502217 A JP2019502217 A JP 2019502217A JP 2019524100 A5 JP2019524100 A5 JP 2019524100A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- immune cell
- car
- nucleic acid
- transposon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002865 immune cell Anatomy 0.000 claims 21
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 102000008579 Transposases Human genes 0.000 claims 10
- 108010020764 Transposases Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 6
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims 5
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000004068 intracellular signaling Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 240000007019 Oxalis corniculata Species 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 241000282832 Camelidae Species 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 101100226902 Mus musculus Fcrlb gene Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000050320 human TNFRSF4 Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363541P | 2016-07-18 | 2016-07-18 | |
| US62/363,541 | 2016-07-18 | ||
| US201662410581P | 2016-10-20 | 2016-10-20 | |
| US62/410,581 | 2016-10-20 | ||
| PCT/CA2017/050860 WO2018014122A1 (en) | 2016-07-18 | 2017-07-17 | Car immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524100A JP2019524100A (ja) | 2019-09-05 |
| JP2019524100A5 true JP2019524100A5 (OSRAM) | 2020-08-27 |
| JP7178568B2 JP7178568B2 (ja) | 2022-11-28 |
Family
ID=60941975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502217A Active JP7178568B2 (ja) | 2016-07-18 | 2017-07-17 | がんを治療するための癌胎児性抗原関連細胞接着分子６を標的とするｃａｒ免疫細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11242386B2 (OSRAM) |
| EP (1) | EP3485017A4 (OSRAM) |
| JP (1) | JP7178568B2 (OSRAM) |
| KR (1) | KR20190057275A (OSRAM) |
| CN (1) | CN109477114A (OSRAM) |
| AU (1) | AU2017299854A1 (OSRAM) |
| CA (1) | CA3031289A1 (OSRAM) |
| IL (1) | IL264223A (OSRAM) |
| PL (1) | PL240585B1 (OSRAM) |
| WO (1) | WO2018014122A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617720B2 (en) * | 2016-10-20 | 2020-04-14 | Miltenyi Biotech, GmbH | Chimeric antigen receptor specific for tumor cells |
| CA3124103A1 (en) * | 2018-12-20 | 2020-06-25 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| CN111041064A (zh) * | 2019-07-22 | 2020-04-21 | 徐州医科大学 | 一种体外评价car-t杀伤活性的方法 |
| JP7769325B2 (ja) * | 2019-07-23 | 2025-11-13 | 株式会社東芝 | Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット |
| EP4190808A4 (en) * | 2020-08-19 | 2024-07-31 | Suzhou Immunofoco Biotechnology Co., Ltd. | Humanized antibody, chimeric antigen receptor, nucleic acid, vector, cell and use |
| KR20230126713A (ko) * | 2020-12-18 | 2023-08-30 | 바이오아르디스 엘엘씨 | Cea6 결합 분자 및 이의 사용 |
| EP4320435A1 (en) * | 2021-04-09 | 2024-02-14 | Achilles Therapeutics UK Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
| JPWO2024084852A1 (OSRAM) * | 2022-10-20 | 2024-04-25 | ||
| WO2025006562A1 (en) * | 2023-06-27 | 2025-01-02 | Bio4T2, Llc | Methods of car administration and treatment |
| WO2025029484A1 (en) * | 2023-07-31 | 2025-02-06 | Bio4T2, Llc | Methods of blood cell-mediated in vivo car cell expansion and engraftment |
| CN120041501A (zh) * | 2023-11-10 | 2025-05-27 | 上海细胞治疗集团药物技术有限公司 | 一种表达嵌合抗原受体的细胞的制备方法 |
| CN120463811A (zh) * | 2025-07-16 | 2025-08-12 | 上海健康医学院 | 一种靶向ceacam6的纳米抗体及其制备方法与用途 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| EP0711303B2 (en) | 1993-07-30 | 2009-06-10 | Affymax, Inc. | Biotinylation of proteins |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1047770A1 (zh) | 2000-02-24 | 2003-03-07 | Xcyte Therapies, Inc. | 细胞的同时刺激与浓缩 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| EP1452601A1 (en) | 2003-02-28 | 2004-09-01 | Roche Diagnostics GmbH | Enhanced expression of fusion polypeptides with a biotinylation tag |
| WO2009003671A2 (en) | 2007-07-04 | 2009-01-08 | Max-Delbrück-Centrum für Molekulare Medizin | Hyperactive variants of the transposase protein of the transposon system sleeping beauty |
| CA2813133C (en) * | 2010-10-01 | 2023-10-31 | National Research Council Of Canada | Anti-ceacam6 antibodies and uses thereof |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| BR112015028387B1 (pt) | 2013-05-13 | 2023-04-11 | Cellectis | Receptor antigênico quimérico específico para cd19, polinucleotídeo, vetor de expressão, método in vitro para manipulação e uso de uma célula imune |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| US20160280798A1 (en) * | 2013-11-06 | 2016-09-29 | The United States Of America, As Represented By The Secretary Department Of Health & Human Service | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| US10494434B2 (en) * | 2013-12-20 | 2019-12-03 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
| CN106535925A (zh) * | 2014-05-23 | 2017-03-22 | 佛罗里达大学研究基金会有限公司 | 基于car的免疫治疗 |
| WO2016073381A1 (en) | 2014-11-03 | 2016-05-12 | Cerus Corporation | Compositions and methods for improved car-t cell therapies |
| EP3018200A1 (en) | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
-
2017
- 2017-07-17 KR KR1020197001589A patent/KR20190057275A/ko not_active Ceased
- 2017-07-17 AU AU2017299854A patent/AU2017299854A1/en not_active Abandoned
- 2017-07-17 WO PCT/CA2017/050860 patent/WO2018014122A1/en not_active Ceased
- 2017-07-17 CA CA3031289A patent/CA3031289A1/en not_active Abandoned
- 2017-07-17 EP EP17830145.3A patent/EP3485017A4/en not_active Withdrawn
- 2017-07-17 PL PL422231A patent/PL240585B1/pl unknown
- 2017-07-17 CN CN201780044780.1A patent/CN109477114A/zh active Pending
- 2017-07-17 JP JP2019502217A patent/JP7178568B2/ja active Active
- 2017-07-17 US US15/651,692 patent/US11242386B2/en active Active
-
2019
- 2019-01-13 IL IL264223A patent/IL264223A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524100A5 (OSRAM) | ||
| JP7390345B2 (ja) | アゴニスト性ｔｎｆ受容体結合物質 | |
| JP2024125370A (ja) | クローディン１８．２結合部分およびその利用 | |
| KR102713223B1 (ko) | 항-pd-l1 항체 | |
| TWI548418B (zh) | Anti-NR10 / IL-31RA antibody and its use | |
| CN110035773B (zh) | 新型抗ctla4抗体 | |
| CN110799540B (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2019511212A5 (OSRAM) | ||
| JP2024091842A (ja) | 抗ｃｄ３抗体及び該抗体を含む分子 | |
| JP2019530431A5 (OSRAM) | ||
| CN111393529B (zh) | 与ox40l非竞争结合的抗ox40抗体 | |
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| JP6608698B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| CN106986939B (zh) | 抗pd-1和tem-8双特异性抗体及其应用 | |
| JP2016514457A5 (OSRAM) | ||
| JP2019506841A5 (OSRAM) | ||
| JP2020530777A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2020512973A5 (OSRAM) | ||
| AU2021238341A1 (en) | Miniature guidance and navigation control (miniGNC) antibody-like proteins and methods of making and using thereof | |
| US20210395380A1 (en) | Variant antibodies that bind ox40 | |
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| JP2023536631A (ja) | 多重特異性結合性作用剤およびその使用 | |
| IL303535A (en) | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof | |
| Sandeep et al. | Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics | |
| EP4242231A1 (en) | Anti-siglec-15 antibody and application thereof in preparing drug |